

June 14, 2019

Sawai Pharmaceutical Co., Ltd.

Upsher-Smith Laboratories, LLC

**UPSHER-SMITH LABORATORIES ENTERS INTO AGREEMENT TO ACQUIRE TOSYMRA™
AND ZEMBRACE® SYMTOUCH®**

Maple Grove, MN – June 13, 2019 – [Upsher-Smith Laboratories, LLC](#) (“Upsher-Smith”, President and CEO: Rusty Field), a subsidiary of Sawai Pharmaceutical Co., Ltd. (“Sawai”, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced that it has agreed to acquire US and other territory rights for Tosymra™ (sumatriptan nasal spray) 10 mg, and Zembrace® SymTouch® (sumatriptan injection) 3 mg from [Dr. Reddy’s Laboratories Limited](#) (“DRL”, Head office: Hyderabad Telangana, India, Co-Chairman and CEO: G.V. Prasad). The products are currently commercialized through DRL’s wholly owned subsidiary, [Promius Pharma LLC](#) (“Promius”, Head office: New Jersey, USA, President: Anil Namboodiripad). Under the terms of the agreement, DRL is eligible to receive an upfront payment, future milestone payments and sales-based royalties.

“This agreement underscores Upsher-Smith’s commitment to significantly expanding its pipeline and diversifying its product portfolio through both internal development and targeted acquisition,” said Rusty Field, President and CEO, Upsher-Smith. “These two products are a great strategic fit for our company, and we look forward to working with Promius Pharma to ensure a smooth product transition.”

About Sumatriptan Formulations

Tosymra™ nasal spray 10 mg, and Zembrace® SymTouch® injection 3 mg are indicated for the acute treatment of migraine with or without aura in adults.

About Upsher-Smith

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought generics and brands to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication to uninterrupted supply.

As Upsher-Smith celebrates its 100-year anniversary, the company enters a new ambitious era that has been accelerated by its 2017 acquisition by Sawai. Upsher-Smith and Sawai plan to leverage each other for growth worldwide and embark on an exciting new chapter as they seek to deliver the best value for their stakeholders, and most importantly, Do More Good™ for the patients they serve. For more information, visit <https://www.upsher-smith.com>.

◆ Contact information ◆

PR / IR Group, Corporate Strategy Department, Sawai Pharmaceutical Co., Ltd.

E-mail: koho@sawai.co.jp